The present invention relates to the field of
biomedicine, and relates to a pharmaceutical use of a hypoxia-inducible
lipid droplet-associated
protein or a truncated fragment thereof. Specifically, the present invention relates to a use of a hypoxia-inducible
lipid droplet-associated
protein or a truncated active fragment thereof in the preparation of a
drug for treating or preventing
hyperlipidemia,
hyperlipidemia complications or neurodegenerative diseases, or a use of the hypoxia-inducible
lipid droplet-associated
protein or the truncated active fragment thereof in the preparation of a
drug for reducing the apolipoprotein level, low-density
lipoprotein level, or very low-density
lipoprotein level in blood or
cerebrospinal fluid.